---
title: "Roivant Shareholders Approve Directors and Governance Matters"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299444057.md"
description: "Roivant Sciences shareholders approved key governance matters at its 2026 Annual General Meeting, including the re-election of directors Daniel Gold and Meghan FitzGerald, ratification of Ernst & Young LLP as auditor, and approval of executive compensation. The company operates in the biopharmaceutical sector with a market cap of $28.58B. Analyst ratings vary, with some suggesting a Buy target of $51.00, while AI analysis labels it Neutral due to strong balance sheets offset by operating losses."
datetime: "2026-09-18T11:47:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299444057.md)
  - [en](https://longbridge.com/en/news/299444057.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299444057.md)
generator: "portal-rs"
---

# Roivant Shareholders Approve Directors and Governance Matters

An update from Roivant Sciences ( (ROIV) ) is now available.

On September 16, 2026, Roivant Sciences Ltd. held its 2026 Annual General Meeting of Shareholders, with approximately 90.3% of eligible common shares represented, establishing a quorum for business. Shareholders re-elected Daniel Gold and Meghan FitzGerald as Class II directors to serve until the annual meeting following the fiscal year ending March 31, 2029, reinforcing continuity in the company’s board leadership.

Investors also ratified the appointment of Ernst & Young LLP as Roivant’s independent registered public accounting firm and statutory auditor for the fiscal year ending March 31, 2027. In addition, shareholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, signaling broad support for the current governance, oversight structures, and executive pay policies.

The most recent analyst rating on (ROIV) stock is a Buy  
 with a $51.00 price target.  
 To see the full list of analyst forecasts on Roivant Sciences stock,  
 see the ROIV Stock Forecast page. 

**Spark’s Take on ROIV Stock**

According to Spark, TipRanks’ AI Analyst, ROIV is a Neutral.

ROIV’s score is supported by a very strong balance sheet and improving business outlook from major positive catalysts (FDA approval and encouraging clinical data), alongside a technically strong uptrend. Offsetting these positives are persistent operating losses and heavy free-cash-flow burn, plus limited valuation support given negative earnings and no dividend yield data.

To see Spark’s full report on ROIV stock,  
 click here. 

**More about Roivant Sciences**

Roivant Sciences Ltd. operates in the biopharmaceutical sector, focusing on developing and commercializing innovative therapies through a portfolio of subsidiary companies. The firm’s model centers on advancing drug candidates efficiently and leveraging partnerships and capital markets to bring new treatments to specialized and underserved patient populations.

**Average Trading Volume:** 6,840,598

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $28.58B

Learn more about ROIV stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)

## Related News & Research

- [If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/303451247.md)
- [Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares](https://longbridge.com/en/news/303810442.md)
- [How Investors May Respond To Roivant Sciences (ROIV) Phase 3 Uveitis Win](https://longbridge.com/en/news/302884227.md)
- [Is SpaceX Stock Worth Buying While It's Below $140?](https://longbridge.com/en/news/304084857.md)
- [Google Says Demand Will Swallow Every Data Center It Builds](https://longbridge.com/en/news/303998103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**